Dadswell Brings Extensive Intellectual Property Experience to Illumina Executive Team
SAN DIEGO--(BUSINESS WIRE)--Apr. 22, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced it has appointed Charles Dadswell as Senior Vice President and General Counsel. Dadswell will assume all functional responsibilities previously held by Christian Cabou, who has retired, and will have worldwide responsibility for all legal and intellectual property matters as well as being Secretary to Illumina’s Board of Directors.
“Chuck brings a deep understanding of the intellectual property and legal issues facing innovative health care companies,” said Jay Flatley, President and Chief Executive Officer of Illumina. “We are excited to welcome him to the team and value the expertise he brings as Illumina continues to grow.”
Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor’s in science from Ferris State University.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
